Background and Objectives Women harbouring HPV genotypes are at risk to develop either genital warts or cervical dysplasia as a precursor of cervical carcinoma. Aim of the study was to evaluate the prevalence of HPV vaccine-genotypes in a female population group.
Materials and Methods Data were collected from 4230 female patients between February and July 2012. Material was either delivered or directly sampled and processed at the Outpatients’ Centre for Diagnosis of Infectious Venero-Dermatological Diseases Vienna. Clinical diagnosis was assessed by the referring physician. Samples were collected and processed using Cytobrush DNAPAP Cervical Sampler and Papillo Check PCR.
Results Out of 1485 patients with “cervical dysplasia and cervical cancer precursors” (PAP III, IIID, IV and CIN I, II, III) 55.2% showed HPV high-risk positivity. Out of this group 35.6% were positive for HPV 16 and 18. Referring to vaccination cross-immunity HPV 31, 33, 45, and 52 were detected in 14.9%, 7.7%, 2.9% and 6.2% respectively.
In women with diagnosis “cervical dysplasia and cervical cancer precursors” an age-related distribution of different genotypes could be observed. HPV 16 and 18 were more often detected in young women (40%) and decreased with increasing age (24%). In contrast, HPV 45 and 56 were more often identified in older women (11.2% vs. 24%).
In specimens of individuals with genital warts HPV low-risk was detected significantly more often when samples were collected in the Outpatients’ Centre than when taken by the referring physician (65.3% vs. 24.8%).
Conclusion HPV high-risk types 16 and 18 were detected especially in the group of young women. It can be considered that vaccination in our young female population would have prevented cervical dysplastic lesions in at least 35.6% of cases. In case of using the quadrivalent vaccine in our study cohort genital warts would have been prevented in 71.2% of cases.
- HPV age distribution
- HPV infection
- HPV vaccination